Redeye comments on Immunicum communicating interim data from its ADVANCE II trial, which we believe confirm positive top-line data that the company presented in December 2021. Further, we judge that ADVANCE II not having reached mRFS and mOS yet bodes well relative to historical controls. We raise our Base Case.